Enhanced Plaque Stabilization Effects of Alirocumab　- Insights From Artificial Intelligence-Aided Optical Coherence Tomography Analysis of the Alirocumab for Thin-Cap Fibroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography (ALTAIR) Study.

Journal: Circulation journal : official journal of the Japanese Circulation Society
PMID: 39313373

Abstract

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors stabilize vulnerable plaque, reducing cardiovascular events. However, manual optical coherence tomography (OCT) analysis of drug efficacy is challenging because of signal attenuation within lipid plaques.

Authors

  • Tetsuya Yamamoto
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Yoichiro Sugizaki
    Clinical Trial Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Hiroyuki Kawamori
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Takayoshi Toba
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan (Y.I., T.T.).
  • Takashi Hiromasa
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Satoru Sasaki
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Hiroyuki Fujii
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Tomoyo Hamana
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Yuto Osumi
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Seigo Iwane
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Hiroshi Tsunamoto
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Shota Naniwa
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Yuki Sakamoto
    Rist Inc., Kyoto, Japan.
  • Koshi Matsuhama
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Yuta Fukuishi
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Hiroya Okamoto
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Kotaro Higuchi
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
  • Shengxian Tu
    Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao Tong University.
  • Ken-Ichi Hirata
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Hospital, 7-5-2, Kusunoki-Cho, Chuo-Ku, Kobe, Japan.
  • Hiromasa Otake
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Keywords

External Resources

Popular Topics
Recent Journals